PHILOGEN SPA (PHIL.MI) Fundamental Analysis & Valuation

BIT:PHIL • IT0005373789

Current stock price

22.5 EUR
-0.05 (-0.22%)
Last:

This PHIL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. PHIL.MI Profitability Analysis

1.1 Basic Checks

  • In the past year PHIL was profitable.
  • PHIL had a positive operating cash flow in the past year.
  • PHIL had negative earnings in 4 of the past 5 years.
  • In the past 5 years PHIL reported 4 times negative operating cash flow.
PHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFPHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 28.81%, PHIL belongs to the top of the industry, outperforming 96.25% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 36.49%, PHIL belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 21.08%, PHIL belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROIC 21.08%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHIL.MI Yearly ROA, ROE, ROICPHIL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • PHIL's Profit Margin of 58.33% is amongst the best of the industry. PHIL outperforms 96.25% of its industry peers.
  • In the last couple of years the Profit Margin of PHIL has grown nicely.
  • PHIL's Operating Margin of 49.47% is amongst the best of the industry. PHIL outperforms 97.50% of its industry peers.
  • PHIL has a Gross Margin of 74.04%. This is in the better half of the industry: PHIL outperforms 63.75% of its industry peers.
  • In the last couple of years the Gross Margin of PHIL has grown nicely.
Industry RankSector Rank
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
PHIL.MI Yearly Profit, Operating, Gross MarginsPHIL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. PHIL.MI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHIL is creating value.
  • The number of shares outstanding for PHIL remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, PHIL has less shares outstanding
  • PHIL has a better debt/assets ratio than last year.
PHIL.MI Yearly Shares OutstandingPHIL.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHIL.MI Yearly Total Debt VS Total AssetsPHIL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • PHIL has an Altman-Z score of 14.12. This indicates that PHIL is financially healthy and has little risk of bankruptcy at the moment.
  • PHIL has a better Altman-Z score (14.12) than 91.25% of its industry peers.
  • PHIL has a debt to FCF ratio of 0.31. This is a very positive value and a sign of high solvency as it would only need 0.31 years to pay back of all of its debts.
  • PHIL has a better Debt to FCF ratio (0.31) than 95.00% of its industry peers.
  • PHIL has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • PHIL has a better Debt to Equity ratio (0.08) than 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Altman-Z 14.12
ROIC/WACC2.65
WACC7.94%
PHIL.MI Yearly LT Debt VS Equity VS FCFPHIL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • PHIL has a Current Ratio of 5.73. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
  • PHIL's Current ratio of 5.73 is amongst the best of the industry. PHIL outperforms 86.25% of its industry peers.
  • A Quick Ratio of 5.52 indicates that PHIL has no problem at all paying its short term obligations.
  • PHIL has a Quick ratio of 5.52. This is amongst the best in the industry. PHIL outperforms 88.75% of its industry peers.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.52
PHIL.MI Yearly Current Assets VS Current LiabilitesPHIL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. PHIL.MI Growth Analysis

3.1 Past

  • PHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 255.77%, which is quite impressive.
  • Measured over the past years, PHIL shows a very strong growth in Earnings Per Share. The EPS has been growing by 100.72% on average per year.
  • Looking at the last year, PHIL shows a very strong growth in Revenue. The Revenue has grown by 3346.54%.
  • Measured over the past years, PHIL shows a very strong growth in Revenue. The Revenue has been growing by 42.46% on average per year.
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%

3.2 Future

  • PHIL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.40% yearly.
  • Based on estimates for the next years, PHIL will show a very strong growth in Revenue. The Revenue will grow by 22.55% on average per year.
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue Next Year112.03%
Revenue Next 2Y-23.41%
Revenue Next 3Y-32.3%
Revenue Next 5Y22.55%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHIL.MI Yearly Revenue VS EstimatesPHIL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PHIL.MI Yearly EPS VS EstimatesPHIL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. PHIL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 19.74, PHIL is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 83.75% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.35. PHIL is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 18.01, which indicates a rather expensive current valuation of PHIL.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 85.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.61, PHIL is valued a bit cheaper.
Industry RankSector Rank
PE 19.74
Fwd PE 18.01
PHIL.MI Price Earnings VS Forward Price EarningsPHIL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 88.75% of the companies in the same industry are more expensive than PHIL, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, PHIL is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.87
EV/EBITDA 11.21
PHIL.MI Per share dataPHIL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PHIL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PHIL has a very decent profitability rating, which may justify a higher PE ratio.
  • PHIL's earnings are expected to decrease with -63.96% in the coming years. This may justify a cheaper valuation.
PEG (NY)1.34
PEG (5Y)0.2
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHIL.MI Dividend Analysis

5.1 Amount

  • No dividends for PHIL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHIL.MI Fundamentals: All Metrics, Ratios and Statistics

PHILOGEN SPA

BIT:PHIL (4/1/2026, 12:58:23 PM)

22.5

-0.05 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-04
Inst Owners9.33%
Inst Owner ChangeN/A
Ins Owners34.46%
Ins Owner ChangeN/A
Market Cap657.90M
Revenue(TTM)78.72M
Net Income(TTM)45.91M
Analysts80
Price Target26.52 (17.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 19.74
Fwd PE 18.01
P/S 8.36
P/FCF 17.87
P/OCF 16.64
P/B 5.23
P/tB 5.28
EV/EBITDA 11.21
EPS(TTM)1.14
EY5.07%
EPS(NY)1.25
Fwd EY5.55%
FCF(TTM)1.26
FCFY5.6%
OCF(TTM)1.35
OCFY6.01%
SpS2.69
BVpS4.3
TBVpS4.26
PEG (NY)1.34
PEG (5Y)0.2
Graham Number10.51
Profitability
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROCE 28.1%
ROIC 21.08%
ROICexc 75.73%
ROICexgc 78.23%
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
FCFM 46.77%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Debt/EBITDA 0.24
Cap/Depr 67.4%
Cap/Sales 3.47%
Interest Coverage 78.84
Cash Conversion 91.98%
Profit Quality 80.19%
Current Ratio 5.73
Quick Ratio 5.52
Altman-Z 14.12
F-Score8
WACC7.94%
ROIC/WACC2.65
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
Revenue Next Year112.03%
Revenue Next 2Y-23.41%
Revenue Next 3Y-32.3%
Revenue Next 5Y22.55%
EBIT growth 1Y218.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.81%
EBIT Next 3Y-71.96%
EBIT Next 5YN/A
FCF growth 1Y1324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6769.31%
OCF growth 3YN/A
OCF growth 5Y135.99%

PHILOGEN SPA / PHIL.MI Fundamental Analysis FAQ

What is the fundamental rating for PHIL stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI.


What is the valuation status for PHIL stock?

ChartMill assigns a valuation rating of 6 / 10 to PHILOGEN SPA (PHIL.MI). This can be considered as Fairly Valued.


What is the profitability of PHIL stock?

PHILOGEN SPA (PHIL.MI) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for PHIL stock?

The Price/Earnings (PE) ratio for PHILOGEN SPA (PHIL.MI) is 19.74 and the Price/Book (PB) ratio is 5.23.


What is the earnings growth outlook for PHILOGEN SPA?

The Earnings per Share (EPS) of PHILOGEN SPA (PHIL.MI) is expected to grow by 14.73% in the next year.